Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Devine, Michael J ^a   Kaganovich, Alice ^b   Ryten, Mina ^a   Mamais, Adamantios ^a   Trabzuni, Daniah ^a   Manzoni, Claudia ^a   McGoldrick, Philip ^a   Chan, Diane ^c   Dillman, Allissa ^b   Zerle, Julia ^a   Horan, Susannah ^a   Taanman, Jan Willem ^a   Hardy, John ^a   Marti Masso, Jose Felix ^d   Healey, Daniel ^a,f   Schapira, Anthony H ^a   Wolozin, Benjamin ^c   Bandopadhyay, Rina ^a   Cookson, Mark R ^b   van der Brug, Marcel P ^e,g   Lewis, Patrick A ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Hospital Donastia   (Spain)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f BEAUMONT HOSPITAL   (Ireland)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTOME;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUCINE RICH REPEAT KINASE 2 GENE; MALE; MUTATIONAL ANALYSIS; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; REGULATOR GENE; BRAIN; CELL STRAIN HEK293; CYTOLOGY; FIBROBLAST; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PLASMID;

AGED; AGED, 80 AND OVER; BRAIN; FEMALE; FIBROBLASTS; HEK293 CELLS; HUMANS; MALE; MUTATION; PARKINSON DISEASE; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 79960677581     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022489     Document Type: Article

References (24)

1. Dachsel JC, Farrer MJ, (2010) LRRK2 and Parkinson disease. Arch Neurol 67: 542-547.
2. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41: 1308-1312.
3. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 41: 1303-1307.
4. Hsu CH, Chan D, Wolozin B, (2010) LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener Dis 7: 68-75.
5. Lewis PA, (2009) The function of ROCO proteins in health and disease. Biol Cell 101: 183-191.
6. Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, et al. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem 112: 1593-1604.
7. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, et al. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. Embo J 27: 2432-2443.
8. Gehrke S, Imai Y, Sokol N, Lu B, (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466: 637-641.
9. Guo H, Ingolia NT, Weissman JS, Bartel DP, (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466: 835-840.
10. Sharma S, Bandopadhyay R, Lashley T, Rentom A, Kingsbury A, et al. (2011) LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Neuropathol Appl Neurobiol epub ahead of press.
11. Sly WS, Grubb J, (1979) Isolation of fibroblasts from patients. Methods Enzymol 58: 444-450.
12. Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, et al. (2010) The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 5: e8730.
13. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
14. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7: 203-205.
15. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, et al. (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 9: 229-245.
16. van der Brug MP, Blackinton J, Chandran J, Hao LY, Lal A, et al. (2008) RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A 105: 10244-10249.
17. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.
18. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
19. Cookson MR, Hardy J, Lewis PA, (2008) Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol 1: 217-231.
20. Mutez E, Larvor L, Lepretre F, Mouroux V, Hamalek D, et al. (2010) Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging.
21. Mortiboys H, Johansen KK, Aasly JO, Bandmann O, (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75: 2017-2020.
22. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, et al. (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8: 267-280.
23. Greggio E, Cookson MR, (2009) Leucine Rich Repeat Kinase 2 mutations and Parkinson's disease: Three Questions. ASN Neuro doi:10.1042/AN20090007.
24. Cookson MR, (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11: 791-797.